FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
Source link
- These stocks are the biggest winners when oil prices surge
- ‘SVB’s failure could and should have been prevented’: Experts argue for better regulation and supervision by the Fed
